27 C
Vientiane
Saturday, April 26, 2025
spot_img
Home Blog Page 248

Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign

The Brand’s Latest Mineral Sunscreen Addresses
Top Consumer Barriers to Daily Sunscreen Use

SUMMIT, N.J., March 31, 2025 /PRNewswire/ — Kenvue Inc. (NYSE: KVUE) continues to push the boundaries of suncare product development with the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. A December 2024 Kenvue research study found that 99% of healthcare providers believe if sunscreen offered better application and aesthetic experiences, patients would use their sunscreen more often1. The new mineral formula addresses these barriers by offering a high SPF with a lightweight, invisible finish. To raise awareness, the #1 suncare brand2 in the U.S. is launching a new campaign with an unexpected partner, actor and WWE Superstar John Cena, who, like the new sunscreen, is known for being invisible.

Actor and WWE Superstar, John Cena, and Dr. Neera Nathan star in latest Neutrogena® Ultra Sheer campaign 'Sunscreen You Can't See'.
Actor and WWE Superstar, John Cena, and Dr. Neera Nathan star in latest Neutrogena® Ultra Sheer campaign ‘Sunscreen You Can’t See’.

Inspired by the legendary ‘You Can’t See Me’ catchphrase, the Sunscreen You Can’t See campaign reinforces that while you may not see Ultra Sheer ® Sunscreen on your skin, the high-SPF mineral formula is working hard to protect you from the harshest UV rays. Joining Cena in the campaign is dermatologist and skin cancer surgeon Dr. Neera Nathan.

“I had a blast working on this campaign. It’s funny, but it also gets across a really important point—wearing SPF every day isn’t something you should skip,” said John Cena. “Neutrogena® Ultra Sheer ® Sunscreen is lightweight, not greasy, and honestly, it’s so sheer you barely notice it’s there.”

“As a dermatologist who removes skin cancers daily, I know sun protection is crucial for preventing sun-induced cancers and photoaging,” says Dr. Neera Nathan. “Ultra Sheer ® Mineral Face Liquid Sunscreen stands out for its lightweight, high-SPF mineral protection and invisible finish, which I hope will encourage more people to wear sunscreen daily.”

The Neutrogena® Ultra Sheer ® Sunscreen collection is designed for everyday wear, offering superior broad-spectrum UVA/UVB protection powered by proprietary Helioplex® and Purescreen® Technology. The advanced, fast-absorbing mineral formula ensures an ultra-light, invisible finish without the heavy, greasy feel, making sunscreen use effortless and enjoyable.

“At Neutrogena®, we’re committed to breaking down barriers to sun protection,” said Andrew Stanleick, Kenvue President of Skin Health & Beauty in North America, Europe, Middle East, and Africa. “By leveraging humor and cultural relevance, we’re making sun safety and daily sunscreen use a conversation people want to engage with, especially younger audiences.”

In 2025, Neutrogena® is strengthening its longstanding commitment to education and awareness for sun safe practices, while increasing the number of dermatologists engaged and sunscreen sampled. As the official sun care sponsor of the Coachella Valley Music and Arts Festival and Stagecoach Festival, the brand will offer complimentary sunscreen stations and education. Additionally, Neutrogena® is deepening its eight-year relationship with the Melanoma Research Foundation, surpassing $1 million in total donations over their relationship and partnering to host activations during Melanoma Awareness Month.

Furthering its impact, the brand will serve as an official sun care sponsor of the 2025 World Surf League, emphasizing the importance of sun protection for beach and water activities. To reach younger audiences, Neutrogena® has partnered with Young Minds Inspired to develop the Sun Safety for All program, providing education to students across the country and fostering lifelong sun protection habits at an early age.

About Kenvue
Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

About Neutrogena®
For over 90 years, Neutrogena® has been developing breakthrough skincare solutions that both advance clinical efficacy and provide incredible product experience, living into our Beauty to a Science platform. From science-led innovation to accessible education, we are driven by a mission to democratize skin health & beauty. Our products address skin needs across ages, skin types and tones. Neutrogena® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of the Neutrogena® Ultra Sheer ® Face Liquid Mineral Sunscreen SPF 70. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.

A list and descriptions of risks, uncertainties and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

1 Sunscreen Perception Survey 2024 (December 2024) Kenvue – Dermsquared®
2 Nielsen L52W ending 12/28

Media Contact: 
Jenni Évora 
Communications Lead, Neutrogena
jevora@kenvue.com

Actor and WWE Superstar, John Cena, and Neutrogena® are redefining the concept of invisible sunscreen.
Actor and WWE Superstar, John Cena, and Neutrogena® are redefining the concept of invisible sunscreen.

 

Actor and WWE Superstar, John Cena, is the global face of the latest Neutrogena® Ultra Sheer SPF campaign.
Actor and WWE Superstar, John Cena, is the global face of the latest Neutrogena® Ultra Sheer SPF campaign.

 

 

XJTLU-Baidu AI joint venture launched

SUZHOU, China, March 31, 2025 /PRNewswire/ — On 26 March, Suzhou Pudu Co-Intelligence Technology Company, a joint venture between Xi’an Jiaotong-Liverpool University (XJTLU) and Baidu Group, was launched as China’s first AI-focused joint venture co-founded by Baidu and a university.

AI+education: Redefining learning

Through AI-driven innovation, Pudu Co-Intelligence seeks to transform the whole education value chain, empower industrial evolution and cultivate localised service ecosystems.

The company will soon launch the Pudu Co-Intelligence AI Forum, bringing together Baidu’s chief scientists, XJTLU’s AI researchers, policymakers, and industry leaders to share their thinking on cutting-edge technologies, AI research, interpretation of relevant policies, and personal experience in industry.

The company will work with local players to integrate AI capabilities into software, intelligent devices, and computing infrastructure, ensuring rapid local response to industry needs that will extend AI’s benefits to all sectors.

In addition to regular Pudu AI forums and an upcoming white paper, the joint venture aims to launch the following:

  • The Pudu Co-Intelligence AI Learning Space, which will feature AI-powered teaching hardware and the company’s large-model training system, offering personalised learning paths, mixed-reality labs, and intelligent evaluation and feedback tools;
  • The Pudu Co-Intelligence Large Model Research Collaboration Platform, which will combine Baidu’s generative AI capabilities with XJTLU’s research scenario insights into a platform to optimise the research cycle, serving as a “super brain” for researchers;
  • The AI+ Professional Certification Programme, to certify the capabilities of academic staff, alumni, and managers in digital transformation; and
  • The Pudu Co-Intelligence Cup AI innovative application competition, which will be held with local governments and enterprises to connect industrial demand with teaching and research.

Pudu Co-Intelligence came from an existing cooperation between XJTLU and Baidu, begun in 2023. Early that year, the two jointly established the XJTLU-PaddlePaddle AI Industry Institute and the Baidu AI Cloud Qianfan Large-Scale Model Platform (Suzhou) Innovation Centre. That September, with the support of the government authority at Suzhou Industrial Park, the XJTLU-Baidu Artificial Intelligence Innovation Alliance was launched.

In 2024, the two parties signed a joint venture agreement. Dr Dou Shen, Executive Vice President of Baidu, remarked: “This joint venture with XJTLU represents Baidu’s deepening commitment to university-enterprise collaboration in AI.”

Professor Youmin Xi, Executive President of XJTLU, said: “By blending research and talent development at universities with real-world industrial scenarios, we can accelerate the translation of research into tangible applications, taking advantage of cutting-edge technologies, including AI.”

Hmong-American Deported to Laos, Family Seeks Support

Hmong-American Deported to Laos, Family Seeks Support
The 37-year-old Ma Yang, a Hmong-American who got deported to Laos in early March and her family. (photo credit: Daily Mail)

Ma Yang, a 37-year-old Hmong-American woman, was deported to Laos on 7 March, leaving behind her five children and long-time partner in Milwaukee, United States. 

Harbour BioMed Reports Full Year 2024 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ — Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.

Throughout the year, Harbour BioMed advanced its strategic transition toward becoming a sustainably profitable global biotech engine. The Company expanded its research and development pipeline with a strong focus on immunology, autoimmune diseases, and inflammation therapeutics. Several key clinical-stage programs progressed significantly, reinforcing our vision of delivering life-changing medicines to patients worldwide.

The Company also made substantial investments in its technology platforms to ensure its core antibody discovery capabilities remain at the forefront of biopharmaceutical innovation. The strategic growth of Nona Biosciences, a subsidiary of Harbour BioMed, further solidified our position as a leading partner in the global biotech ecosystem. Additionally, we strengthened our business collaborations, securing multiple licensing and co-development agreements with top-tier pharmaceutical companies to drive sustainable revenue growth.

As we look ahead to 2025, we remain committed to expanding our global presence and delivering breakthrough therapies to patients.”

Full Year 2024 Financial Highlights

Harbour BioMed reported total revenue of US$38.1 million for the year ended December 31, 2024, with an overall profit of approximately US$2.7 million. The company has been profitable for two consecutive years, demonstrating the uniqueness and resilience of its business model.

Compared to 2023, the company’s revenue sustainability has continued to improve. Annual recurring revenue increased from US$5.7 million to US$16.9 million, reflecting a growth rate of 196.5%. Cash profit[1] reached a record high of US$30.68 million. Meanwhile, Harbour BioMed has maintained a strong financial position. As of December 31, 2024, the company’s cash and cash equivalents totaled approximately US$166.8 million, providing a solid financial foundation for future growth.

[1] cash profit: operating net cash inflow.

Advancing a Robust and Differentiated Pipeline

Harbour Therapeutics, a sub-brand parallel to Nona Biosciences, is now individually responsible for the development of the Company’s products pipeline. With a growing focus on immunology, inflammation and oncology, Harbour Therapeutics manages a highly differentiated portfolio that includes multiple innovative drug candidates in both clinical and Investigational New Drug (IND)/IND-enabling stages.

In inflammation and immunology, the Company has built a robust preclinical pipeline encompassing bispecific and multi-specific antibodies generated using the HCAb-based Bispecific Immune Cell Antagonist (HBICATM) technology, as well as ultra long-acting biotherapeutics for immune-related diseases.

In oncology, the Company is leveraging its HBICE® platform to develop bispecific and multi-specific antibodies with novel designs and differentiated mechanisms, such as HBM9027 (PD-L1xCD40) and HBM7004 (B7H4xCD3). In addition, the Company is utilizing its Harbour Mice® and XDC platforms to explore multiple therapeutic modalities, including HBM9033, a mesothelin-targeted ADC, and other ADC/RDC programs in early-stage development.

Main products in the clinical stage include:

Batoclimab (HBM9161) is the first anti-FcRn monoclonal antibody completed Phase I to pivotal trials in China. As a novel, fully human anti-FcRn monoclonal antibody, batoclimab has the potential to be a breakthrough treatment option for a wide range of autoimmune diseases. In December 2023, the Company voluntarily planned to include additional long-term safety data and re-submitted the Biologic License Application (BLA) for batoclimab to the National Medical Products Administration of China (NMPA) in June 2024. In July 2024, NMPA accepted the BLA for batoclimab for the treatment of gMG. The Phase III pivotal clinical trial results of batoclimab were published in JAMA Neurology in March 2024, demonstrating sustained efficacy and safety with long-term use of batoclimab in the treatment of gMG.

HBM9378 is a fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) generated from the H2L2 Harbour Mice® platform. It is a co-development project conducted by the Company and Kelun-Biotech, with both parties equally sharing the rights. HBM9378 has fully human sequences with a lower immunogenicity risk and better bioavailability compared to other TSLP-targeting competitors. Its long half-life optimization and outstanding biophysical properties support favourable dosing and formulation advantages.

  • The Company received IND approval of HBM9378 for moderate-to-severe asthma from the NMPA in February 2022 and completed a Phase I clinical trial in healthy subjects in China. In November 2024, the Company submitted an IND application for HBM9378 for chronic obstructive pulmonary disease (COPD) to the NMPA, which was approved in February 2025.
  • In January 2025, the Company and Kelun-Biotech entered into an exclusive license agreement with Windward Bio, under which Windward Bio was granted an exclusive license for the research, development, manufacturing and commercialization of HBM9378 globally (excluding Greater China and several Southeast and West Asian countries). Currently, Windward Bio is preparing a global Phase II clinical trial for HBM9378.

Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice® platform. It is also the first fully human heavy-chain-only antibody which entered clinical development globally. Compared with conventional CTLA-4 antibodies, porustobart has unique, favourable properties, including significant Treg cell depletion and optimized pharmacokinetics for improved safety. Additionally, by enhancing antibody-dependent cellular cytotoxicity (ADCC), porustobart increases the potential to selectively deplete intratumoral Treg cells, helping to overcome the efficacy and toxicity bottleneck of current CTLA-4 therapies. The Company has implemented a global development plan for multiple types of solid tumors with an adaptive treatment design for porustobart. Positive efficacy and safety data have been observed in the monotherapy trial targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC.

HBM1020 is a first-in-class fully human monoclonal antibody generated from the H2L2 Harbour Mice® platform targeting B7H7. As a newly discovered member of the B7 family, B7H7 expression is found to be non-overlapping with PD-L1 expression in multiple tumor types, potentially playing a more significant role in tumor immune evasion. With its excellent product design and target features, HBM1020 presents great potential to address significant unmet medical needs for solid tumors. In September 2024, the Company presented the latest clinical data for patients with advanced solid tumors at the ESMO Congress 2024. The data demonstrated excellent safety and tolerability profiles for HBM1020. Of the 15 patients who received post-treatment tumor assessments, 7 patients (46.7%) achieved stable disease (SD), with two patients showing tumor shrinkage of 11% and 25%.

Main products in IND and IND-enabling stages include:

HBM7020 is a BCMAxCD3 bispecific antibody generated using the fully human HBICE® bispecific technology and Harbour Mice® platform. HBM7020 can crosslink targeted cells and T cells by binding to BCMA and CD3 on the cell surface, leading to potent T cell activation and cell elimination. By incorporating dual anti-BCMA binding sites for optimal cell targeting and monovalent-optimized CD3 activity to minimize CRS, HBM7020 demonstrated potent cytotoxicity with broad applications in both immunological and oncology diseases. In August 2023, HBM7020 obtained IND clearance from the NMPA to commence a Phase I trial for cancer in China. In 2024, the Company restructured its development strategy to target immunological diseases and is currently preparing an IND application.

HBM9027 is a novel PD-L1xCD40 bispecific antibody developed using the HBICE® bispecific antibody technology and Harbour Mice® platform. The development of PD-L1xCD40 bispecific antibody further expands the Company’s bispecific immune cell engager into the cutting-edge DC/myeloid cell engager field, showcasing the HBICE® platform’s versatile geometry formats and plug-and-play advantages. In January 2024, HBM9027 obtained IND approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial in the U.S.

HBM7004 is a novel B7H4xCD3 bispecific antibody. Using HBICE® bispecific technology and Harbour Mice® platform, this bispecific antibody was designed to provide innovative solutions for cancer immunotherapy from both efficacy and safety perspectives. The development of B7H4xCD3 bispecific HBICE® further consolidates the Company’s bispecific immune cell engager platform, demonstrating the HBICE® platform’s versatility and plug-and-play advantages. In preclinical studies, HBM7004 demonstrated an intratumor B7H4-dependent T cell activation manner. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable in vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window. The Company is currently conducting IND-enabling studies for HBM7004.

HBM9014 is a first-in-class, fully human antibody targeting leukemia inhibitory factor receptor (LIFR) for cancer treatment. It was discovered using the Harbour Mice® platform. HBM9014 blocks multiple IL-6 family cytokine pathways via LIFR to inhibit their function in promoting tumor progression, metastasis and chemoresistance. In preclinical studies, HBM9014 showed significant in vivo antitumor efficacy and enhanced efficacy in combination with cisplatin in multiple tumor models. In addition, HBM9014 exhibited strong tolerability in toxicology studies conducted on primates. In 2025, the Company will continue to actively explore drug development strategies and seek collaboration opportunities.

Strategic Business Collaborations Maximizing Platform Value

Harbour BioMed’s ongoing commitment to global partnerships is critical to driving both scientific and commercial success. In 2024, the Company continued expanding its business collaborations with leading academic institutions and select industrial partners, focused on driving innovation and efficiency worldwide.

Leveraging its technological advantages, Harbour BioMed established Nona Biosciences to better empower industry innovators and support collaborators from Idea to IND (I to ITM). Nona Biosciences is a global biotechnology company committed to providing integrated solutions for partners worldwide, across academia, biotechnology startups, and biopharmaceutical giants. Since its launch in late 2022, Nona Biosciences has achieved remarkable success, securing numerous international collaborations across various innovative formats. The subsidiary has established four leading technology units based on HCAb, including protein engineering, conjugation technology, delivery technology, and cell therapy, to accelerate the development of next-generation therapies.

Nona Biosciences signed a global out-license and option agreement with AstraZeneca in May 2024 for preclinical monoclonal antibodies to be used in developing targeted oncology therapies. In December 2024, Nona Biosciences entered a research collaboration and license agreement with Candid Therapeutics to discover next-generation T-cell engagers. Over the past year, Nona Biosciences has also formed research collaborations with multiple partners across various therapeutics areas, including Boostimmune, Alaya.bio, Umoja Biopharma, Alkyon Therapeutics, OverT Bio, and Kodiak Sciences.

In January 2025, the Company announced a license agreement with Windward Bio for HBM9378, an anti-TSLP fully human antibody for immunological diseases. In February 2025, HBM Alpha Therapeutics, an innovative biotechnology company incubated by the Company, announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

These collaborations further highlight the Company’s unique strengths in pushing technological boundaries and exploring new innovation pathways. With its industry-leading technology platforms and a flexible business model, the Company will continue seeking new opportunities to expand its collaboration network and maximize the value of its platforms.

Incubating Breakthrough Collaborations for the Future

To fully harness the potential of its unique platform technologies, Harbour BioMed continues to explore the scalability of its platform applications. The Company is incubating several joint ventures focused on next-generation therapeutics, ranging from multivalence antibodies to cell therapies. These ventures aim to broaden the application of platform technologies and create additional value for the Company. This innovative incubation model facilitates the integration of incremental resources for the diversified development of next-generation innovations, requiring minimal marginal investment while offering a high return on value growth. Representative projects include HBM Alpha Therapeutics and Shanghai NK Cell Technology Limited.

2025 Outlook: Expanding Global Presence and Driving Innovation

Looking ahead to 2025, Harbour BioMed will continue driving business growth and accomplishing its mission through two key pillars, Harbour Therapeutics and Nona Biosciences. Harbour Therapeutic will advance multiple clinical trials of its internal pipeline to fully advance the global clinical development project, while Nona Biosciences will continue providing integrated discovery solutions to biotech and pharmaceutical companies, ultimately fostering an innovation ecosystem that promotes biological advancement.

A range of products derived from the Company’s Harbour Mice® technology platform and T-cell engager technology will be advanced in immunology, and the ADC platform will be upgraded to the next generation. Through a combination of in-house development and business collaborations, Harbour BioMed will build a portfolio of products with differentiated competitive advantages both in immunology and immuno-oncology.

Maximizing the value of its platform through strategic collaborations will continue to drive the Company’s global expansion. In 2025, as the preclinical product pipeline matures, the company expects to expand its collaboration network even further and enter into broader global partnerships, solidifying its leading position in the global market.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

SINGAPORE, March 31, 2025 /PRNewswire/ — Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process.

Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and other commodities in highly energetically favorable (high yield, high purity) production. Allozymes is optimizing key enzymes in the pathway to meet large-scale production specifications. The collaboration includes Allozymes’ cutting edge microfluidics-based protein engineering platform to achieve what was previously thought impossible: analyzing up to 20 million enzyme variants a day, delivering superior success rates, and dramatically reducing development timelines for novel enzymes.

“Optimizing enzymes for industrial-scale production requires precision, speed, and innovation, and our collaboration with Bonumose exemplifies this,” said Akbar Vahidi, Chief Technology Officer of Allozymes. “By leveraging our microfluidics-based protein engineering platform, we have been able to rapidly enhance key enzymes, significantly improving the process efficiency and scalability. The early results are promising, and we are confident that this partnership will unlock new possibilities in sustainable and cost-effective ingredient production.”

Dr. Daniel Wichelecki, Bonumose’s Chief Scientific Officer and Co-Founder, states, “Our mission is to produce healthy food and supplement ingredients in a low-cost, scalable production process. Our development collaborator Allozymes has shown promising results in the initial phases of our collaboration. We are on track and confident to meet our developmental objectives.”

The companies are pleased with the important milestone in both companies’ agenda of leveraging the use of enzymes to accelerate timelines and meet ambitious targets for producing beneficial ingredients to meet global needs for healthy food, dietary supplements, and other important categories.

“Our goal is to drive the future of sustainable food ingredient production through enzyme innovation,” said Akbar Vahidi. “Our collaboration with Bonumose is a critical part of this mission and we aim to demonstrate a successful model on how Allozymes enables innovation in the food ingredient market. With our unique platform, we are confident that we’ll continue to reduce development timelines and enhance performance, setting a new benchmark in the industry.”

About Allozymes

Allozymes is a biotechnology company that stands out in the bio-engineering sector with its proprietary ultra-high throughput microfluidics platform for the rapid and cost-effective development of enzymes, microbes, and biomanufactured ingredients. This technology sets a new standard for innovation and sustainability, enabling the development of robust biosolutions across various sectors. By leveraging its ultra-high screening power, Allozymes aims to build the world’s largest enzyme data library, addressing both current and future needs for advancing the bioeconomy.

Learn more at www.allozymes.com.

About Bonumose

Bonumose is a later-stage startup food ingredient and enzyme innovation company based in Albemarle County, Virginia, United States. Bonumose is supported by strategic investors, “food for health”-focused institutional investors, and a network of global collaboration partners across the value chain. Bonumose developed and patented the Bonumose® method for continuous production of high-purity tagatose and other good-for-you ingredients from abundant, plant-based feedstocks. Beyond sugar alternatives, Bonumose also has solutions for dietary supplements, crop protection, animal nutrition, and other globally significant industries. Bonumose operates with a philosophy of Business as a Moral Imperative and believes in the power of market incentives to solve intractable problems. Bonumose’s tagatose is certified/verified as Prebiotic, Ketogenic, Non-GMO, Plant-Based, Vegetarian, Kosher and Halal.

MEXC Unveils MNT Promotion Offering Up to $1 Million in Rewards

VICTORIA, Seychelles, March 31, 2025 /PRNewswire/ — MEXC, a leading global cryptocurrency exchange, has announced a groundbreaking partnership with Mantle (MNT) to launch an exclusive month-long trading campaign with a prize pool of up to $1,000,000, offering users an opportunity to earn substantial rewards.

MEXC Unveils MNT Promotion Offering Up to $1 Million in Rewards
MEXC Unveils MNT Promotion Offering Up to $1 Million in Rewards

The event presents a range of valuable opportunities for users:

  • Zero trading fees on MNT Spot and Futures markets, helping users reduce costs and optimize returns.
  • Up to 500% APR through MNT staking, offering one of the most competitive yields currently available.
  • Token rewards via Launchpool, where users can stake USDT, MX, or MNT to earn additional MNT tokens and exclusive benefits.

Additionally, users can join the Deposit & Trade campaign, designed with a low entry threshold—ideal for newcomers looking to explore the ecosystem. For seasoned traders, the Futures Trading Competition provides a platform to demonstrate their trading expertise, climb the leaderboard based on trading volume, and compete for a share of the $300,000 prize pool.

Event Overview

Period: March 31, 2025, 10:00 – April 30, 2025, 10:00 (UTC)

During the event period, users can participate in the following MNT-related activities on the platform by clicking on the links below.

Event 1: MNT trading (Spot and Futures) is available with zero trading fees.

Event 2: Users who deposit and trade MNT on the Spot market may qualify to share a pool of 113,340 MNT.

Event 3: MNT staking offers returns of up to 500% APR, subject to platform terms.

Event 4: A Futures Trading event allows participants to compete for a share of 300,000 USDT in bonus rewards.

Event 5: The MNT Launchpool enables users to stake selected tokens in exchange for a portion of 240,000 MNT in rewards.

As a pioneering Layer-2 scaling solution for Ethereum, Mantle uses Optimistic Rollup technology to lower transaction costs and improve network performance. This collaboration highlights MEXC’s leadership in backing innovative blockchain projects and its unwavering commitment to offering users diverse, cutting-edge trading opportunities, lowering costs and helping them maximize their potential returns.

Looking ahead, MEXC is committed to continuously enhancing the trading experience by introducing innovative features, expanding user opportunities, and launching new initiatives aligned with the dynamic nature of the cryptocurrency market.

For further details on the event, please see the official announcement.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 34 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.

MEXC Official Website X Telegram |How to Sign Up on MEXC

Risk Disclaimer:

The information provided in this article regarding cryptocurrencies does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, the fundamentals of projects, and potential financial risks before making any trading decisions.

PXPay Plus and J.P Morgan Asset Management Taiwan Join Forces to Launch Industry-First Direct Fund Dividend Direct Deposit into E-Wallet Accounts

Endless Growth of Wealth: Reinvest Dividends into Micro-Investment Funds

TAIPEI, March 31, 2025 /PRNewswire/ — “Digital Hen” is a fund investment service jointly launched by PXPay Plus and Fund swap, integrating payment and investment functions. It is designed for beginner investors and budget-conscious individuals, allowing them to invest while they spend. The service offers two investment options: “Spare Change Saving” and “Regular Saving.”

Chairman of J.P Morgan Asset Management Taiwan-Henry Tong & General Manager of PXPay Plus-Kennith Yu
Chairman of J.P Morgan Asset Management Taiwan-Henry Tong & General Manager of PXPay Plus-Kennith Yu

Since its launch, it has achieved impressive results, gaining nearly 10,000 new users in Q4 2024 compared to Q3. On average, Digital Hen users have seen a return of approximately 10.9% (investment always carries risks; fund investments may gain or lose value; please read the prospectus carefully before subscribing). This service also makes it easier for beginner investors to build their wealth.

Following the launch of the “Digital Hen” service, PXPay Plus is once again expanding its footprint in financial innovation! Today (27th), PXPay Plus announced a partnership with J.P Morgan Asset Management Taiwan, a global leader in asset management, to launch a new service integrating  e-wallet with asset management. This service allows users to flexibly utilize their fund dividend earnings, enhancing daily convenience and quality of life while achieving their ideal financial goals.

With this innovative service, investors can have their fund dividends deposited directly into their PXPay Plus account balance, which can then be used for daily expenses. Additionally, by participating in designated promotional campaigns, users can earn “PXPay Plus Points” (1 PXPay Plus Point = 1 TWD, which can be redeemed for purchases). Alternatively, they can leverage the “Digital Hen” service to allocate small amounts of change into investments, reducing financial risks through diversification.

This service not only makes wealth management easier but also enables smarter spending! It offers investors a more flexible and diverse approach to asset utilization, creating a new experience in both financial management and payments.

※ Investment involves risks. Fund investments may result in gains or losses. Please read the fund prospectus carefully before making any investment decisions.※

First Ever in the Industry: Fund Dividends Deposited Directly into E-Wallet Accounts

J.P Morgan Asset Management Taiwan has been deeply rooted in the local market for 40 years and was the first foreign asset management company in Taiwan to offer online fund trading. By providing a diverse range of financial products and services, it integrates quantitative data with qualitative expertise to ensure clients benefit from convenient financial solutions.

Henry Tong, Chairman of J.P Morgan Asset Management Taiwan, emphasized that “products” and “customers” are the two core values of the company. Recognizing the growing demand for fund dividends, J.P Morgan Asset Management Taiwan has partnered with PXPay Plus to launch an innovative service, “Dividend Deposit into PXPay Plus” This new financial solution integrates PXPay Plus as one of the fund dividend deposit channels, allowing dividends to be directly credited to PXPay Plus accounts. This enhances capital utilization efficiency and offers dividend fund investors an additional option to use their earnings for daily expenses.

General Manager of PXPay Plus, Kennith Yu, highlighted that J.P Morgan Asset Management Taiwan is a globally trusted investment partner that stays ahead of market trends. Through this collaboration, PXPay Plus aims to achieve three key objectives: First, to attract more new users. Secondly, increase users’ consuming power to raise the transaction volume, since they have deposited their fund dividends into PXPay Plus wallet. Last of all, foster more cross-industry cooperation, creating opportunities to develop a more diverse financial platform. 

9 Funds Eligible for “Dividend Deposit to PXPay Plus” – Earn PXPay Plus Points with Qualifying Purchases!

To celebrate the launch of its new financial service, PXPay Plus is offering a special reward program for users. From April 1 to December 31, 2025, PXPay Plus members who are also users of the J.P Morgan Asset Management Taiwan DIRECT investment platform, who participate in the “Dividend Deposit to PXPay Plus” program and have at least one successful dividend deposit into a given month can earn  500 PXPay Plus Points by making a single purchase of NTD 500 or more using PXPay Plus in the following month.(This offer applies only to domestic J.P Morgan Asset Management Taiwan funds) Each user can receive a maximum of 500 PXPay Plus Points per month, up to 4,000 PXPay Plus Points throughout the campaign period.

For Example:

Scenario A:Hu-Li(The mascot of PXPay Plus) subscribes to a designated J.P Morgan Asset Management Taiwan fund before 4:00 PM on April 7, 2025, and links  their PXPay Plus account to receive fund dividends. In April 2025, the fund dividends are successfully credited to their PXPay Plus account. On May 2, 2025, Hu-Li makes a single purchase of NTD 568 at RT-Mart using PXPay Plus and receives 500 PXPay Plus Points as a reward.

Scenario B- Pang-P(Mascot of PXPay Plus) previously subscribed to a designated J.P Morgan Asset Management Taiwan fund and updated their dividend deposit method to PXPay Plus before March 31, 2025. In April 2025, the fund dividends are successfully credited to their PXPay Plus account. On May 5, 2025, Pang-P makes a single purchase of NTD 888 at RT-Mart using PXPay Plus,  Pang-P then receives 500 PXPay Plus Points as a reward. On the other hand, if users who do not receive fund dividends in April 2025 will not be eligible for the reward in May.)

Looking to  the future, this collaboration marks the beginning of a long-term partnership between PXPay Plus and J.P Morgan Asset Management Taiwan. Both companies aim to develop more innovative financial services, making fintech solutions accessible across different social sectors while enhancing platform competitiveness and market influence. Furthermore, PXPay Plus and J.P Morgan Asset Management Taiwan will continue to offer diverse and customized financial management and payment services, helping users achieve long-term financial goals while  creating a smarter, more convenient financial lifestyle.

Attachment 1

Promotion Period: 2025 April 1st to 2025 December 31st

Eligible Participants: This promotion is open to all PXPay Plus members who are also J.P Morgan Asset Management Taiwan DIRECT investment platform customers at the time of cashback calculation.

Promotion Details:

  • How to participate:

Log in to J.P Morgan Asset Management Taiwan DIRECT: PXPay Plus members must log in to the J.P Morgan Asset Management Taiwan DIRECT investment platform. Link the  Fund Dividend to PXPay Plus account, set up the deposit of domestic fund dividends to the PXPay Plus wallet. After identity verification and successful linking, the PXPay Plus membership number will appear in the fund account information under “My Account” > “Withdrawal/Deposit Account” > “Dividend Deposit Bank/Account”. : When a J.P Morgan Asset Management Taiwan domestic fund reaches the distribution threshold for the current month, the dividend will be credited to the PXPay Plus wallet.

  1. Only domestic J.P Morgan Asset Management Taiwan funds qualify for the dividend deposit to PXPay Plus accounts. If the fund is an international J.P Morgan Asset Management Taiwan fund, the dividend will be credited to the previously set bank account, and the user will not be eligible for this event.
  2. If a fund does not reach the distribution threshold for dividends in a given month, the dividend will not be credited to PXPay Plus, and the user will not be eligible for the event’s rewards. Please refer to the fund prospectus for the specific distribution threshold.
  3. You can view dividend deposit records in the PXPay Plus App under “My” > “Transaction Records”.
  • Boosting spending power:

Once the user  qualifies for the event, they can earn 500 PXPay Plus Points by making a single purchase of NTD 500 or more in the following month. Eligible purchases can be made with your PXPay Plus balance account, linked bank account, or linked credit card, including payments for domestic and international purchases.

The 500 PXPay Plus Points promotion points will be awarded starting in May 2025. Each customer can receive the reward once per month, up to 8 times during the event period.. The final month for receiving rewards is December 2025. A total of 5,000,000 PXPay Plus Points will be distributed, allocated on a first-come, first-served basis, until the total allocation is exhausted..

Example 1:

Your J.P Morgan Asset Management Taiwan domestic fund’s dividend is successfully credited to your PXPay Plus account in April (qualifying for the event). On May 3, 2025, you make a NTD 550 purchase with PXPay Plus wallet (meeting the NTD 500 minimum), and you will immediately receive 500 PXPay Plus Points. If you make another purchase on May 10, 2025, the reward will not be issued again in May as you are only eligible for one reward per month.

Example 2:

Your J.P Morgan Asset Management Taiwan domestic fund’s dividend is successfully credited to your PXPay Plus account in mid-April (qualifying for the event). If you make a purchase of NTD 600 on April 28, 2025, you will not receive the reward because the reward is applicable to purchases made in the month following the dividend deposit.The PXPay Plus Points will be issued by  PXPay Plus Co., Ltd., and the event is concurrent with other PXPay Plus promotions.

  • This collaboration with J.P Morgan Asset Management Taiwan is limited to fund dividends being deposited into PXPay Plus. Users cannot use PXPay Plus to purchase J.P Morgan Asset Management Taiwan funds, nor can they use PXPay Plus to make fund subscriptions or redemptions. Fund subscriptions and redemptions must be made through the J.P Morgan Asset Management Taiwan DIRECT platform.

About PXPay Plus

PXPay Plus, an e-wallet brand founded and 100% fully owned by the PX Mart Group. In June of 2021, PXPay Plus obtained licenses and approval for operating electronic payment related business from the FSC (Financial Supervisory Commission) in Taiwan. Continuing the company culture of the PX Mart group, building a delightful company environment for everyone. With the launch of PXPay Plus, users can now enjoy enhanced wallet features, providing a seamless and secure payment experience.

Clinical Study demonstrates Kerry Group Supplement Solution Sensoril® Ashwagandha Supports Quality of Life for Post-Menopausal Women

Sensoril® Ashwagandha is among Kerry’s portfolio of solutions tailored to meet women’s unique health needs  

SINGAPORE, March 31, 2025 /PRNewswire/ — Sensoril® ashwagandha — a science-backed ingredient by Kerry Group — has been shown to support quality of life for women post menopause, according to a new clinical study.

With the potential for women to spend up to 40% of their life post menopause, it is crucial those years are enjoyable.1 This recently published study validates Sensoril’s unique ability to support symptom management and quality of life in women post menopause, at as low as 250mg/day.

This research builds on the existing 14 scientifically backed studies that show the natural ingredient is a safe and effective solution to support overall health.

Hormonal changes associated with menopause can lead to negative symptoms like hot flashes, mood swings, and sleep disturbances. Approximately 80% of women experience these symptoms, making it a common but typically overlooked or ignored aspect of women’s health.2 In Asia Pacific, 64% of women experience pre-menopausal symptoms that impact their emotional health and 62% who are perimenopausal, menopausal or post-menopausal say they would be interested in nutritional supplements that help them manage their symptoms.3

Despite the frequency of these symptoms, the impact of menopause on ageing has not been considered widely in research, leading to gaps in women’s healthcare.4 With one billion women estimated to be experiencing menopause in 2025, these shortcomings must be addressed.5

Increasingly, the use of herbal, plant-based treatments for managing menopausal symptoms has been gaining popularity as many women seek more natural alternatives to hormone replacement therapy. Sensoril, a unique, standardised, synergetic combination of the ashwagandha root and leaf, directly meets this need. With demonstrated efficacy, Sensoril can be a key, natural ingredient integrated into solutions specifically targeted toward women. 

Participants in the clinical study reported decreases across key known menopause symptoms, including:

  • 24% decrease in presence and severity of vasomotor symptoms such as hot flashes, sweating, and night sweats. 
  • 16% decrease in presence and severity of psychosocial symptoms such as poor memory, anxious feelings, lower productivity, dissatisfaction with personal life, and more.  
  • 14% decrease in presence and severity of physical symptoms related to sleep, fatigue, strength, stamina, energy, appearance, aches and pains, and more.
  • 13% decrease in presence and severity of changes in sexual health such as decrease in sexual desire, intimacy avoidance, and vaginal dryness.

“Women are seeking support for their wellbeing where their specific female health needs are understood and met with the right product at the right time,” said Dr. Monica Maria Olivares, RDA Director, Women & Infant Health at Kerry. “This study further supports the current and extensive research naming Sensoril a safe and effective solution. Driving progress in women’s health is of vital importance to us at Kerry, which is why we have curated a suite of naturally sourced and clinically studied ingredients that support women across every life stage. “